REPR....recession-proof stock just starting to report exploding high-margin sales and positive EPS (main product sales up 86%, net income up 414%) while forecasting more of both going forward as their main product (Freedom60) is the only FDA approved of its kind so no direct competition AND approved to be paid for by Medicare. REPR reminds me of a baby ZYXI which exploded 650% this year yet held most of its gains through the awful Sept-Oct crash.
REPR is 1 or 2 quarters away from +.02 EPS per quarter or more or an annualized +.08 EPS pace IMO. A PE of mere 10 = .80/share.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.